Efficacy, Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity Study of Ravulizumab in Chinese Adults With Neuromyelitis Optica Spectrum Disorder (NMOSD)

Starting soon · Phase 3

Conditions studied: NMOSD, Neuromyelitis Optica Spectrum Disorder

In brief

The primary objective of this study is to confirm the efficacy, safety, pharmacokinetics (PK), pharmacodynamics (PD), and immunogenicity of ravulizumab in the treatment of Chinese adults with anti-aquaporin-4 (AQP4) antibody (Ab) + neuromyelitis optica spectrum disorder (NMOSD).

Key facts

Study ID

NCT07557420

Run by

Alexion Pharmaceuticals, Inc.

People needed

21

Starts

2026-08-31

Expected to finish

2028-10-31

Last updated by the study team

2026-06-18

Who can join

Age: 18 and older, up to 130. Sex: any. Healthy volunteers: not accepted.

Where it is running

• Research Site — Chengdu, China
• Research Site — Dongguan, China
• Research Site — Shanghai, China
• Research Site — Wenzhou, China
• Research Site — Wuhan, China

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.